Search research articles
Contact Us
Filters
Showing results (201-210 of 221) with videos related to
Page
of 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597
Daniel D Karp, Sandra J Lee, Steven M Keller, et al.
Clinical Lung Cancer
|
May 27, 2022
Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening Population
Harris Majeed, Hong Zhu, Sarah A Williams, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 26, 2024
Geographic Accessibility and Completion of Initial Low-Dose CT-Based Lung Cancer Screening in an Urban Safety-Net Population
Sofia Yi, Rutu A Rathod, Vijaya Subbu Natchimuthu, et al.
Research Square
|
December 8, 2025
Tobacco use and perceived risk of lung cancer in a safety-net population
Mary E Gwin, Heidi A Hamann, Tanushree Prasad Ma, et al.
Lancet (London, England)
|
July 28, 2009
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Kathy S Albain, R Suzanne Swann, Valerie W Rusch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer
Roy S Herbst, David H Johnson, Eric Mininberg, et al.
JCO Clinical Cancer Informatics
|
March 7, 2025
Virtual Health Care Encounters for Lung Cancer Screening in a Safety-Net Population: Observations From the COVID-19 Pandemic
Mary E Gwin, Urooj Wahid, Sheena Bhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 22, 2006
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
Thomas J Lynch, Alex A Adjei, Paul A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2005
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
David A Eberhard, Bruce E Johnson, Lukas C Amler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 3, 2007
Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer
Pinar B Yildiz, Yu Shyr, Jamshedur S M Rahman, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 221) with videos related to
Sort By:
Page
of 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597
Daniel D Karp, Sandra J Lee, Steven M Keller, et al.
Clinical Lung Cancer
|
May 27, 2022
Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening Population
Harris Majeed, Hong Zhu, Sarah A Williams, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 26, 2024
Geographic Accessibility and Completion of Initial Low-Dose CT-Based Lung Cancer Screening in an Urban Safety-Net Population
Sofia Yi, Rutu A Rathod, Vijaya Subbu Natchimuthu, et al.
Research Square
|
December 8, 2025
Tobacco use and perceived risk of lung cancer in a safety-net population
Mary E Gwin, Heidi A Hamann, Tanushree Prasad Ma, et al.
Lancet (London, England)
|
July 28, 2009
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Kathy S Albain, R Suzanne Swann, Valerie W Rusch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer
Roy S Herbst, David H Johnson, Eric Mininberg, et al.
JCO Clinical Cancer Informatics
|
March 7, 2025
Virtual Health Care Encounters for Lung Cancer Screening in a Safety-Net Population: Observations From the COVID-19 Pandemic
Mary E Gwin, Urooj Wahid, Sheena Bhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 22, 2006
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
Thomas J Lynch, Alex A Adjei, Paul A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2005
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
David A Eberhard, Bruce E Johnson, Lukas C Amler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 3, 2007
Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer
Pinar B Yildiz, Yu Shyr, Jamshedur S M Rahman, et al.
Page
of 23